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We quantified the impact of
treatment-related uncer-
tainties on delivered dose in
intensity modulated proton
therapy for oropharyngeal
cancer patients by simulating
approximately 3700 treat-
ments of 10 patients. Large
dose deviations can occur
especially when various
errors are combined. We
quantified the effect of
adaptive planning on
improvement of treatment
quality and investigated how
plan robustness changes
when more beam directions
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http://dx.doi.org/10.1016/j.ijrobp.2013.09.014Purpose: Setup, range, and anatomical uncertainties influence the dose delivered with intensity
modulated proton therapy (IMPT), but clinical quantification of these errors for oropharyngeal
cancer is lacking. We quantified these factors and investigated treatment fidelity, that is, robust-
ness, as influenced by adaptive planning and by applying more beam directions.
Methods and Materials: We used an in-house treatment planning system with multicriteria
optimization of pencil beam energies, directions, and weights to create treatment plans for 3-,
5-, and 7-beam directions for 10 oropharyngeal cancer patients. The dose prescription was
a simultaneously integrated boost scheme, prescribing 66 Gy to primary tumor and positive neck
levels (clinical target volume-66 Gy; CTV-66 Gy) and 54 Gy to elective neck levels (CTV-54
Gy). Doses were recalculated in 3700 simulations of setup, range, and anatomical uncertainties.
Repeat computed tomography (CT) scans were used to evaluate an adaptive planning strategy
using nonrigid registration for dose accumulation.
Results: For the recalculated 3-beam plans including all treatment uncertainty sources, only
69% (CTV-66 Gy) and 88% (CTV-54 Gy) of the simulations had a dose received by 98% of
the target volume (D98%) >95% of the prescription dose. Doses to organs at risk (OARs)
showed considerable spread around planned values. Causes for major deviations were mixed.
Adaptive planning based on repeat imaging positively affected dose delivery accuracy: in the
presence of the other errors, percentages of treatments with D98% >95% increased to 96%
(CTV-66 Gy) and 100% (CTV-54 Gy). Plans with more beam directions were not more robust.
Conclusions: For oropharyngeal cancer patients, treatment uncertainties can result in significant
differences between planned and delivered IMPT doses. Given the mixed causes for major devia-
tions, we advise repeat diagnostic CT scans during treatment, recalculation of the dose, and if
required, adaptive planning to improve adequate IMPT dose delivery.  2013 Elsevier Inc.Department of Radiation
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(31) 10 704 17 48; E-mail:
A.C. Kraan is currently at Istituto Nazionale di Fisica Nucleare
Sezione di Pisa, Pisa, Italy.
Conflict of interest: none.
Supplementary material for this article can be found at
www.redjournal.org.
, pp. 888e896, 2013
r Inc. All rights reserved.
Volume 87  Number 5  2013 Dose uncertainties in head-and-neck IMPT 889Introduction
Intensity modulated proton therapy (IMPT) uses proton pencil
beams with varying position and energy, whose intensities are
optimized individually. Oropharyngeal tumors form an attractive
site for IMPT because of their complex shape and proximity to
organs at risk (OARs). Improved OAR sparing is expected
compared to intensity modulated radiation therapy (IMRT) (1, 2),
potentially resulting in reduced negative side effects. In IMPT,
however, uncertainties may exist that cause the delivered dose to
seriously deviate fromplanning and thus reduce the benefit of IMPT.
These uncertainties include anatomical changes (eg, organ motion,
changes in air cavities, tumor regression, weight loss), patient setup
errors and range uncertainties from uncertainties in computed
tomography (CT) Hounsfield units (HU), conversion of HUs into
stopping power; and reconstruction artifacts (3-8).
Various works discuss IMPT treatment uncertainties (2-4, 6, 8)
and mitigation by robust optimization (4, 9-16). Many studies
focusing on dose impacts of treatment uncertainties (3, 4, 6, 8)
show one or few patient cases, do not include oropharyngeal
patients, or do not include combined effects of treatment uncer-
tainties. Robust optimization studies (4, 9-16) typically present
results obtained with robust treatment plans (ie, to confirm the
effectiveness of a particularly robust algorithm. In this context, for
head-and-neck cancer patients, a recent article by Liu et al (9)
focused on differences between various robust optimization
strategies to compensate range and patient setup errors. However,
the impact of anatomical changes and realistic simulation of all
treatment-related uncertainties was not presented. Simone et al (2)
compared adaptive IMRT with IMPT for head-and-neck cancer
patients but did not investigate the impact of range and setup
errors. Despite the concerns for robustness of IMPT for head-and-
neck cancer and the interest to treat head-and-neck cancer with
IMPT, a realistic and comprehensive overview of the effects of
treatment uncertainties on the delivered dose is still lacking.
Furthermore, such studies are needed, a priori, to assess the
required level of robustness mitigation in clinical practice.
This study presents a realistic and accurate (3700 simulations
from 10 oropharyngeal cancer patients) analysis of the effects of
treatment uncertainties ondelivereddose. First,we studied the impact
of anatomy, range, and setup errors, separately and in combination
with simulating realistic treatments. Moreover, we evaluated the
effect of range and setup errors of different magnitudes. Results for
target and OARs are readily interpreted in terms of doseevolume
histogram (DVH) parameters. Second, we investigated 2 approaches,
not yet reported, to making treatments robust and applicable inde-
pendent of robust optimization by posing the questions: (1) how is
treatment precision affected by adaptive planning ie, replanning
based on repeated imaging, as recommended in IMRT (17)?; and (2)
does plan robustness improve by choosing more beam directions, as
postulated by Unkelbach et al (4)?Methods and Materials
Patient group
We included 10 prospectively selected oropharyngeal cancer patients
treated at Erasmus Medical Center in 2004 and 2005, aged 48 to 83
years old (mean, 60 years old) (Table 1). Each patient had a planning
and a repeat CT scan, the latter at 46 Gy. Scans were enhanced byadministration of intravenous contrast (100 mL of Omnipaque, 647
mg of iohexol per mL [see Discussion]). The primary tumor was
delineated by a radiation oncologist on eachCT. Contouring ofOARs
was assisted by atlas-based autosegmentation (18) and edited if
needed. Artifact reduction software (19) was used for 5 patients with
metal teeth implants. The dose prescription was a simultaneously
integrated boost scheme, prescribing 66 Gy to the primary tumor and
positive neck levels (CTV-66 Gy) and 54 Gy to elective neck levels
(CTV-54 Gy) in 30 IMPT fractions. CTV volumes are shown in
Table 1. We defined the planning target volumes (PTV)-66 Gy and
PTV-54 Gy as the CTV-66 Gy and CTV-54 Gywith a 5-mmmargins.
Being aware thatmargin recipes are not fully valid for IMPT,we recall
that thiswould be sufficient in IMRT to account for setup errors of 1.5
mmstandard deviationon systematic and randomcomponents (1, 20).
We quantified the amount of anatomical change between the 2 CTs as
the average deformation of salivary glands and primary tumor
measured in 6 directions, as suggested by Vasquez-Osorio et al (21)
(Table 1, last column).
Proton delivery system
We used the pencil beam scanning techniques from Hong et al
(22) and Kooy et al (23). The proton energy ranged from 45 MeV
to 230 MeV. Range shifters were applied when needed for lower
energies. The distance between energy layers was 2 mm in water.
The full width at half the maximum (FWHM) of the pencil beam
ranged from 9 mm at 230 MeV to 21 mm at 45 MeV (numbers for
5 cm of air excluding range shifters [22, 23]).
Planning technique
Treatment planning used an in-house-developed IMPT treatment
planning system. The proton dose calculation algorithm from Hong
et al (22) and Kooy et al (23) was integrated in an automated plan
generation platform called iCycle (24, 25). It performed multicriteria
optimization, which optimized objectives sequentially according to
a list of prioritized objectives and hard constraints, identical for all-
patients. The minimal PTV dose was a hard constraint, while priori-
tized objectives included (in order of priority) minimizing maximum
PTV dose, target conformality, and minimization of dose to all OARs
and unspecified tissues (see Supplementary Fig. E1 for details).
We applied a newly developed method of iterative resampling of
randomlyplacedpencil beams (26).Thedosegrid resolutionwas3 3
 3 mm3.
For each patient, treatment plans with 3, 5, and 7 beam
directions were created for planning and repeat CT.
The 3-beam plan is the basis against which dose deviations and
adaptive planning strategy were quantified and has coplanar
beams at 50, 50, and 180 as published previously (1). We
generated plans with 5 and 7 beam directions with uniformly
spaced angles, starting at 0, to investigate robustness versus more
beams. Examples of dose distributions are shown in Figure 1.
Simulation and quantification of dose deviations
Anatomical uncertainties
These were modeled by calculating the treatment plan dose for frac-
tions 1 to 15 on the planningCTand for fractions 16 to 30 on the repeat
CT. Dose accumulation for OARs and target, both subject to defor-
mation, of the first and second part of the treatment was performed
with an in-house-developed nonrigid registration method (21).
Table 1 Summary of patient characteristics
Patient Site
TNM
staging
Planning CT:
Volume CTV-66 Gy
(cm3)
Planning CT:
Volume CTV-54 Gy
(cm3)
Repeat CT:
Volume CTV-66 Gy
(cm3)
Repeat CT:
Volume CTV-54 Gy
(cm3)
Average
deformation*
(mm)
1 Base of tongue T1N2c 106 199 82 176 4.2
2 Base of tongue T3N2a 99 313 73 268 3.3
3 Tonsil T2N1 43 165 37 156 2.5
4 Tonsil T2N0 11 77 9 75 3.1
5 Soft palate T2N0 14 72 10 67 2.4
6 Base of tongue T3N2a 68 221 47 191 6.6
7 Tonsil T2N0 5 67 5 72 2.3
8 Tonsil T1N1 41 95 35 87 2.5
9 Base of tongue T3N3 178 343 132 296 6.6
10 Base of tongue T1N2c 70 294 63 252 4.5
Patient
average
63 185 49 164 3.8
Abbreviations: CTZ computed tomography; CTV-66 GyZ Clinical Target Volume receiving 66 Gy (primary tumor and positive neck levels); CTV-
54 Gy: Clinical Target Volume receiving 54 Gy (elective neck levels).
* Average deformation was measured in 6 directions as suggested by Vasquez Osorio et al (21).
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These were simulated by recalculating the treatment plans on a CT
scan with all CT numbers systematically increased or decreased
by a given percentage of its value, as proposed by Lomax et al (3).
We investigated shifts in CT numbers ranging from 5% to þ5%
with steps of 1%. Negative (positive) values represent an over-
shoot (undershoot) of the Bragg peak.Fig. 1. Dose distributions for patient 4. (Top) planned dose for 3 (a
delivered to repeat CTwhen treated with original 3-beam plan, and (e) d
original CT. Target is shown in white; organs at risk (cord, parotids, orSetup uncertainties
We simulated an online patient setup correction protocol with
bony anatomy as reference. Ideally, setup errors are zero after
applying online corrections. Residual errors, however, remain
from intrafractional motion or uncorrected deformations of the
bony structures (7). These were simulated by applying rigid iso-
center shifts in anteroposterior (AP), superior-inferior (SI), and), 5 (b), and 7 (c) beam directions. (Bottom, d) calculated dose
elivered dose when applying a 4-mm posterior isocenter shift to the
al cavity) are in yellow.
Fig. 2. Example of doseevolume histograms of patient 1 with various errors included for 5 sets of simulations. For visualization, we
show only the target regions and 2 organs at risk.
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treatments of 30 fractions each. For each simulated treatment, we
did the following:
 A systematic shift (dAP,dSI,dRL) was applied, fixed for all
fractions. The size of each d (AP, SI, or RL) was determined
randomly and independently from a normal distribution with
standard deviation S (20).
 A random shift (DAP,DSI,DRL) was applied, varying for each
fraction. The size of each D was determined randomly from
a normal distribution with standard deviations (20).We assumed
that sZ S (20).
 The total isocenter shift for each fraction was determined,
which was the vector sum of the above-described 2 contribu-
tions; and a dose matrix was calculated for each fraction.
 The resulting 30 dose matrices of all fractions was added to
obtain the total dose for 1 treatment.
This was repeated 40 times, yielding 40 dose matrices per
patient, representing 40 treatments. We repeated this procedure for
S Z s Z 1.0, 1.5, 2.0, 2.5, and 3.0 mm.
All uncertainties combined
We investigated the combined effect of all errors by including
them simultaneously. We included a range shift of 3% (3) and
setup errors S Z s Z 1.5 mm (both following the procedure
above for both planning and repeat CT), corresponding to the
average residual setup error from bony anatomy deformation (7).We applied the treatment plan to the planning CT for fractions 1 to
15 and to the repeat CT for fractions 16 to 30. Nonrigid regis-
tration was used for dose accumulation between the CTs. We
simulated 40 treatments of 30 fractions, yielding 40 dose distri-
butions per patient.
Improving treatment quality
Adaptive planning
We investigated the effect of adaptive planning (adaptive planning
based on repeat imaging) on treatment quality by repeating the
simulations and including all errors as described above, but now
applying for fractions 16 to 30 a newly created plan based on the
repeat CT. Forty treatments were simulated per patient.
Increased beam directions
Analogue to the 3-beam plans, we simulated 40 treatments that
included all errors for 5 and 7 beam directions (see section “All
uncertainties combined”, above above) to investigate whether plan
robustness improved when applying more beam directions.
In summary, for each patient we performed 291 treatment
simulations for 3-beam directions (nominal situation: 1 simula-
tion; range error: 9 simulations; anatomical uncertainty: 1 simu-
lation, setup error: 40  5Z 200 simulations; combined errors: 40
simulations; adaptive plan: 40 simulations), 40 simulations for 5-
beams, and 40 simulations for 7-beams. For 10 patients this
resulted in a total of 3710 treatment simulations.
Fig. 3. (a) For the 10 patients, impact of various uncertainties on target dose are shown. Solid markers represent medians, boxes are
spread between the 25th and 75th percentiles, and lines extend to the minimum and maximum of the 40 simulations. Because CTV-54 Gy
contains CTV-66 Gy region, the V107% and D98% of CTV-54 Gy are naturally high for all patients. (b) For the 10 patients, impact of
various uncertainties on organs at risk are shown. (figure 3b is displayed on the following page) Markers are as shown in panel a.
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Plan evaluation was based on DVH following ICRU recommenda-
tions (27) (Fig. 2). For CTV-66 Gy and CTV-54 Gy, we considered
the percentages of the target volumes receiving at least 95% and
107% of the prescribed dose (V95% and V107%, respectively) (27)
and dose received by 98% of the target volume (D98%) (27). For
cord and brainstem, we report dose to 2% of the volume (D2%) for
near maximum dose (27), while for other OARs, we report mean
doses (27). Statistical analysis of the differences among the plans for
3, 5, and 7 beam directions used the ANOVA test (a P value <.05
was considered significant).
Results
Below we report the dose deviations in our simulated treatments
and corroborate our findings with the treatment intent that 90% of
the patient population should have D98% 95% (20). We also
highlight a few large dose deviations.
Quantification of dose deviations
Anatomical errors
Figure 1d shows an example of the dose degradation that resulted
from applying the treatment plan from the planning CT to therepeat CT. Figure 3 summarizes dose effects for all simulations.
For the target (Fig. 3a, “anatomical error”), the effect of
anatomical errors was clearly visible in the D98%. The increase in
target hot spots was small, except for patient 9 (V107% Z 14%
[see Supplementary Fig. E2]). Anatomical errors had a negative
impact, but D98% for all patients was >95%. For CTV-66 Gy and
CTV-54 Gy, the average D98% reduction was 1.9% and 2.1%,
respectively. For CTV-66 Gy, the V107% increase due to
anatomical errors was correlated with its size (Pearson correlation,
0.76; PZ.011) and a trend toward a moderate correlation was
observed for the average deformation (Pearson correlation, 0.64;
PZ.058). The biggest increase in OAR dose (Fig. 3b, “anatomical
error”) was in patient 6, with a 9.2Gy increase in the brainstem
(see Supplementary Fig. E3).
Range error
Figure 4 (left panels) shows the impact of range errors. For
CTV66-Gy, we note that for range errors within 4%, more than
90% of the patient population has D98% 95%, whereas for
CTV54-Gy, even larger range errors do not cause a violation.
Figure 3 shows the impact of a 3% range error on target (Fig. 3a)
and OARs (Fig. 3b). For CTV-66 Gy and CTV-54 Gy (spaces
don’t look good) the average D98% reductions were 2.0% and
2.2%, respectively. The average increase for the 10 patients in
D2% (for cord, brainstem) and mean dose (for other OARs) was
less than 1 Gy for all OARs.
Fig. 3. (continued)
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Figures 1a and 1e demonstrate the impact of a 4-mm rigid iso-
center shift on delivered dose. Figure 4 (right panels) shows the
effects of setup errors. All parameters show an increase in target
dose deterioration with increasing setup errors. At S Z s Z 2
mm (CTV-66 Gy), the treatment intent that 90% of the populationhave D98% >95%, was not satisfied anymore. Figure 3a (“setup
error”) summarizes the dose effects for S Z s Z 1.5 mm for
target. For both CTVs, the median reduction in D98% was small,
although with a large spread around the median. The largest
D98% spread in CTV-66 Gy was seen in patient 4 with a relatively
small tumor. For OARs (Fig. 3b), we quantified the effect of the
Fig. 4. Influence of range (left) and setup (right) uncertainties on target coverage. For the range error, maximum, minimum, and
percentiles refer to the statistics of the group of 10 patients. For the setup error, they refer to 400 simulations (40 simulations  10 patients).
Planned values correspond to an error of zero.
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deviation, and maximum values across all simulations of the
delivered minus the planned maximum (cord, brainstem) or
mean (other OARs) dose. The average dose increase across all
simulations was less than 1 Gy for each OAR, although some
large variations between individual treatments were observed
(Fig. 3a).
All errors combined
Figures 3a and 3b show that the combination of errors can lead to
inferior treatments. For CTV-66 Gy and CTV-54 Gy, percentages ofsimulations withD98%>95%were only 69% and 88%, respectively
(Table 2), which is clinically unsatisfying. Hot spots increase: the
average increase in V107% (ie, delivered minus planned V107%)
across all simulations was 5.1% in V107% (CTV-66 Gy) and 2.9%
(CTV-54 Gy). For OARs, we found average dose increases below 1
Gy but again large variations among treatments were present. The
largest variation was in the right parotid, with a standard deviation in
meandose difference of 3.6Gy and amaximumdifference of 11.3Gy
(see Supplementary Fig. E4). The spinal cord showed a standard
deviation in the maximum dose difference of 2.2 Gy and a maximum
difference of 9.5 Gy (see Supplementary Fig. E5).
Table 2 Percentage of simulations satisfying D98% 95%
(or V95% 98%)
Patient
All errors Replanning
CTV-66 Gy CTV-54 Gy CTV-66 Gy CTV-54 Gy
1 88% 100% 92% 100%
2 90% 95% 100% 100%
3 75% 98% 100% 100%
4 40% 90% 85% 100%
5 28% 95% 98% 100%
6 82% 100% 100% 100%
7 68% 20% 90% 98%
8 95% 98% 100% 100%
9 60% 100% 100% 100%
10 62% 82% 100% 100%
All patients 69% 88% 96% 100%
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Adaptive planning
Figure 3 and Table 2 demonstrate how adaptive planning posi-
tively affects dose delivery. Target coverage showed a clear
increase. For CTV-66 Gy and CTV-54 Gy, 96% and 100%,
respectively, of simulations had a D98%>95%, now safely
complying with the treatment intent that 90% of the population
has D98% >95% (Table 2). Target hot spots decreased compared
to the scenario were no adaptive planning was applied: the
delivered minus planned V107% was now only 1.5% (CTV-66
Gy) and 2.0% (CTV-54 Gy). For OARs, the dose spread was
reduced. For patient 4, the spinal cord dose was reduced greatly
due to the lower cord dose in the repeat CT plan.
More beam directions
Supplementary Figure E6 shows dose effects for plans with 3, 5,
and 7 beam directions. As shown in Supplementary Figure E6,
plans with 5 or 7 beam directions were not significantly more
robust than plans with 3 beam directions.
Discussion
An important observation is that the errors individually do not lead
to serious target underdosage (D98%<95%) but that combined
effects of the errors generate serious problems and cause the
treatment intent (D98% 95% for at least 90% of the patient
population [20]) to not be fulfilled. We recommend for IMPT
studies that simulations combine all uncertainties to study site-
specific clinical robustness requirements.
Concerning anatomical deformations, 1 of the 10 patients had
a significant increase in hot spots. This patient had substantial
target volume shrinkage (178 to 132 ml for CTV-66 Gy) (Table 1),
deformation (6.6 mm [Table 1]), and weight loss, resulting in
incorrect spatial pencil beam matching in the target (see
Supplementary Fig. E2 for details). Patient 6, with similar
deformation, did not show serious target hot spots but instead
showed a large dose increase to the brainstem (see Supplementary
Fig. E3). Small changes in V107% were seen in patients 3, 5, 7,
and 8, with small CTV volumes and small deformations (2.3-2.5
mm). Factors such as initial tumor size can help to estimate whichpatients risk large dose deviations, as shown by the significant
correlation between the increase in V107% and the tumor size. On
the other hand, only a moderate correlation was found between
increase in V107% and deformation. Much higher patient statis-
tics and a thorough classification of anatomy changes (tumor
shrinkage, weight loss, swelling, and others) are needed to identify
patients at risk. In the absence of accurate prognostic factors,
repeat imaging, dose recalculation, and, if required, adaptive
planning are recommended to ensure sufficient target coverage
and to avoid unwanted exposure of OARs. The timing and
frequency of repeated imaging are subjects for future research.
We found no dramatic dose modifications when studying range
errors separately. This is a significant clinical observation, as
range errors are considered one of the primary concerns in robust
optimization algorithms. A different spot placement technique
could alter this, as shown by Lomax et al (3).
In the simulations that include setup errors, median dose devi-
ations are small, but the dose spread is large both for OARs and
target. Dose deteriorations in the target are caused by incorrect
spatial matching of pencil beams, resulting in target hot spots, and
by target misalignment (Figs. 1e and 3a). The impact on V95% is
seen to be largest for small tumors (Table 1, patients 4 and 7), which
is explained by the larger relative impact of a misalignment on these
small volumes. The 5-mm CTV margin helps to account for target
misalignment but cannot fully avoid dose impacts. Robust optimi-
zation could reduce the contribution of this error source (9). In
addition, based on Figure 4, it is highly recommended that the
systematic and random setup errors (S and s, respectively) are kept
below 2 mm, for instance by the use of online image guidance. This
would alsowork to deal with problems such as a different position of
the neck at planning and during treatment.
Concerning combined errors, the simulations (Fig. 3) showed
that the combined occurrence of errors can amplify negative dose
effects. We saw for patient 6 a large dose increase in the brainstem
(see Supplementary Fig. E3), where the combined effect of the
errors was larger than the sum of the effects separately (Fig. 3b).
This was also observed for the cord of patient 8 (see
Supplementary Fig. E5). Given the mixed causes for deviations,
dose distortions are very difficult to predict without recalculating
the dose with uncertainties included.
Treatment accuracy can be substantially improved by applying
adaptive planning, increasing the percentage of treatmentswithD98%
>95% safely to above 90%.Because adaptive planning increases staff
workload and costs, the optimal adaptive strategy would have to be
defined. Treatment plans with more beam directions were instead not
more robust, in contrast to what was suggested by by Unkelbach et al
(4). We suggest that the use of more beam directions does not neces-
sarily solve dose deteriorations resulting from pencil beam mis-
matching or anatomical changes. We are aware that the choice of
uniformly spacedbeamanglesmaynot be optimal and that beamangle
optimization (28) may result in a more optimal choice, which could
alter our observation. Other ways to improve treatment robustness not
investigated here are to use wider pencil beams (however, this is ex-
pected toworsenOAR sparing [29]) or to apply robust optimization to
dampen the effect of range and patient setup errors (9).
A limitation of this study is that intrafractional setup errors (ie,
changes in patient position during the fraction) were not modeled
separately and dose calculation errors were not included. Both are
expected to have only minor dose impact (3, 30). We verified that
the contrast fluid in our CTs, which led to a slight increase in
inhomogeneities and thereby possibly influenced the simulations,
did not alter our results.
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Based on 3700 simulated treatments for oropharyngeal cancer
patients, we quantified the dose differences between planned and
delivered IMPT doses in targets and OARs. Without action against
treatment uncertainties, the treatment intent (D98% 95% for at
least 90% of the patient population) was not fulfilled. Given the
mixed causes for major deviations observed, we advise acquisition
of repeat CT scans and dose recalculation to properly assess
delivered dose. If required, adaptive planning is effective for
mitigating the effect of treatment-related uncertainties. Applying
more than 3 beam directions did not increase plan robustness.
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